HRT Provides No Heart Benefit, Increases Risk of Blood Clots and Gallstones
July 4, 2002
Hormone replacement therapy did not reduce the risk of heart problems in 2,763 postmenopausal women with coronary heart disease participating in the Heart and Estrogen/progestin Replacement Study (HERS) for 6.8 years, according to a new report published in JAMA. In a companion article, HRT doubled the risk of thromboembolism (blood clots) (relative hazard = 2.08, 95% CI, 1.28-3.40). Three HRT-group participants died of thromboembolic events. HRT also increased the likelihood of gallbladder surgery (RH = 1.48, 95% CI, 1.12-1.95). The HERS study is funded by Wyeth-Ayerst Research.
Grady D, Herrington D, Bittner V, et al. Cardiovascular disease outcomes during 6.8 years of hormone therapy. JAMA. 2002;288:49-57.
Hulley S, Furberg C, Barrett-Connor E, et al. Noncardiovascular disease outcomes during 6.8 years of hormone therapy. JAMA. 2002;288:58-66.
Subscribe to PCRM's Breaking Medical News.
Breaking Medical News is a service of the Physicians Committee for Responsible Medicine, 5100 Wisconsin Ave., Ste. 400, Washington, DC 20016, 202-686-2210. Join PCRM and receive the quarterly magazine, Good Medicine.